Multi-Omic Approaches to Solve Post-Acute COVID-19 (MOSAIC)
The purpose of this study is to facilitate early detection of ME/CFS in people with Long COVID and better understand disease progression.
at Uppsala University
Established in 2019, this research center is directed by Jonas Bergquist, MD, PhD. Prior to this new center, Dr. Bergquist had already been researching ME/CFS for nearly a decade. Dr. Bergquist and his lab develop novel methods for extracting patient samples and measuring the metabolites and proteins within those samples.
Latest Video
They then apply these methods to produce unique and valuable data from a range of diseases. Along with ME/CFS, his lab has a general interest in neurodegenerative diseases such as Parkinson’s, Alzheimer’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
The ME/CFS CRC at Uppsala University is looking for ME/CFS biomarkers to develop a diagnostic test and to contribute to the understanding of what initiates the disease process. Not only are they looking for single metabolites or proteins, they are looking for the pattern of all the data the extract from ME/CFS patient samples and are working towards a defining biochemical signature of the disease.
This collaborative research initiative is looking to develop methods to measure proteins, peptides and metabolites in the blood and cerebrospinal fluid of ME/CFS patients to help define the underlying biological cause, to form a diagnostic and to ultimately find treatments for the disease.
The purpose of this study is to facilitate early detection of ME/CFS in people with Long COVID and better understand disease progression.
The study aims to investigate how hormone fluctuations in individuals with ME/CFS and Long COVID, compared to healthy controls, impact metabolism and immune pathways by measuring hormones, metabolites, and inflammation markers in biofluid samples.
The Life Improvement Trial (LIFT) aims to investigate two drugs, separately and in combination, Pyridostigmine (commonly known as Mestinon) and Low-Dose Naltrexone (LDN), for efficacy and to research the difference between responders and non-responders.
This study seeks to understand the biological mechanisms driving the symptomatology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using metabolomic and lipidomic high-throughput analysis and high-frequency blood sampling over a 6.5 to 7.5 hour period conducted at two separate sites (Melbourne and Uppsala).
We propose an initial explanation for how ME/CFS could originate and perpetuate by drawing on findings from critical illness and heat stroke research.
The goal of this research is to reveal more information about the role of immunology and neuroinflammation in ME/CFS, and the underlying mechanisms of related pathogenesis that takes place.
The clinic in Uppsala continues the work of the OMF-Funded MultiCenter Collaborative Study on COVID to ME/CFS progression.
This study provides a unique opportunity to bring the lab directly into patient homes and provide immediate analysis of samples over an extended period of time.
This longitudinal approach without the invasive and/or PEM-induced measures will be vitally important in other patient cohorts and will decrease the study impact on patients from using more invasive and impactful measures (use of 1 peripheral vein catheter for all blood samples, limits the impact on patients).
Decode the molecular mechanisms underlying ME/CFS and contributing to specific symptoms with a particular emphasis of post-exertional malaise (PEM). This includes deep phenotyping of ME patients and global proteomic/metabolomics plasma profiling of ME..
The publication describes the overlaps between prolonged critical illness and ME/CFS. The hypothesis is that mechanisms that prevent recovery in some intensive care unit patients may also underlie people with ME/CFS.
This study is designed to explore the hypothesis that deranged flow of the cerebrospinal fluid (CSF) due to craniocervical obstructions and/or instability may cause deranged intracranial pressure (ICP), neuroinflammation and cardinal symptoms of ME/CFS.
The aim is to investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid samples between ME/CFS patients and healthy controls.
This study provides an excellent opportunity to understand the mechanism of long-lasting viral-induced cognitive complications, commonly referred to as “brain fog.”
The purpose of the study is to evaluate whether kynurenine is directly connected to ME/CFS patient symptom severity.
Uppsala University (Sweden)
Jonas Bergquist, MD, PhD, Prof, Director
Kumari Ubhayasekhera, PhD
Ganna Shevchenko, PhD
Levon Manukyan, PhD
Sandy Abujrais, PhD Student
Mark Dennis Retrato, PhD Student
Annie Bynke, Med Student
Hanna Gustafsson, Med Student
Torsten Gordh, MD, PhD, Prof em
Massachusetts General Hospital (Harvard)
In Memoriam – Ronald Tompkins, MD, ScD
Wenzhong Xiao, PhD
Stanford University
Ronald Davis, PhD
Karolinska Institut (Sweden)
Per Julin, MD, PhD
Bragee Clinics Stockholm
Bo C. Bertilsson, MD, PhD
Björn Bragée, MD
Kent Nilsson, MD
Gunnar Olsson, MD, PhD, Ass. Prof
Jonas Axelsson, MD, PhD, Ass. Prof
Britt Bragée, RPT, PhD
Gabriella Bernhoff RPT, PhD Student
Brandon Drum, Med Student
Michael Fahlqvist, MD-internship
Michos Anastasios, MD
Gottfries clinic (Sweden)
CG Gottfries, MD, PhD, Prof em
Linkoping University (Sweden)
Anders Rosén, MD, PhD, Prof em
Björn Ingelsson, PhD, Ass prof
Eirini Apostoulo, PhD, Post doc
Rizwan Muhammad, Guest Researcher
University of East Anglia (UK)
Simon Carding, PhD, Prof
Please help us expand our research efforts across the globe. Every donation brings us closer to a fully-funded research effort and the answers we all seek.